Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

2.82
-0.0600-2.08%
Post-market: 2.78-0.0427-1.51%18:58 EDT
Volume:2.43M
Turnover:6.87M
Market Cap:261.33M
PE:-6.10
High:2.89
Open:2.84
Low:2.75
Close:2.88
52wk High:13.99
52wk Low:2.61
Shares:92.67M
Float Shares:83.05M
Volume Ratio:0.51
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4626
EPS(LYR):-0.5438
ROE:-33.63%
ROA:-21.56%
PB:2.06
PE(LYR):-5.19

Loading ...

Anavex Life Sciences meldet im ersten Quartal (Q1) ein Forschungs- und Entwicklungsaufwand von 4,66 Mio. USD, ein Rückgang um 55 Prozent

Reuters
·
Feb 09

Anavex Life Sciences Corp: Net Loss for the Quarter of $5.7 Million, or $0.06 per Share

THOMSON REUTERS
·
Feb 09

Anavex Life Sciences Corp: Anticipates at Its Current Cash Utilization Rate, an Approximate Cash Runway of More Than 3 Years

THOMSON REUTERS
·
Feb 09

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

GlobeNewswire
·
Feb 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 09

Anavex Life Sciences ernennt Wolfgang Liedtke zum Global Head of Neurology

Reuters
·
Feb 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 06

Anavex Life Sciences Corp. kündigt Bekanntgabe neuer Finanzergebnisse an

Reuters
·
Feb 03

Anavex Life Sciences on Track for Highest Close Since November 2025 -- Data Talk

Dow Jones
·
Jan 21

Anavex Joins ACCESS-AD Consortium to Advance Precision Medicine in Alzheimer’s Disease

Reuters
·
Jan 13

BRIEF-Anavex Life Sciences Appoints Senior Vice President Global Head Of Neurology

Reuters
·
Jan 08

Anavex Life Sciences Appoints Wolfgang Liedtke as Senior Vice President, Global Head of Neurology

Reuters
·
Jan 08

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 06

Anavex Life Sciences Corp - Discussion on Potential Pathways for Nda for Alzheimer's Treatment

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Corp: Existing Data From Phase Iib/Iii Anavex2-73-Ad-004 Program Requested by Agency Will Be Submitted

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Corp - FDA Shows Interest in Anavex's Development Plans

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

GlobeNewswire
·
Jan 06

Anavex Life Sciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 22, 2025

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 19, 2025

Anavex Life Sciences Corp - Requests Ema to Re-Examine Blarcamesine for Alzheimer's

THOMSON REUTERS
·
Dec 18, 2025